These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study. Iaffaldano P; Lucisano G; Manni A; Paolicelli D; Patti F; Capobianco M; Brescia Morra V; Sola P; Pesci I; Lus G; De Luca G; Lugaresi A; Cavalla P; Montepietra S; Maniscalco GT; Granella F; Ragonese P; Vianello M; Brambilla L; Totaro R; Toscano S; Malucchi S; Petracca M; Moiola L; Ferraro D; Lepore V; Mosconi P; Ponzio M; Tedeschi G; Comi G; Battaglia MA; Filippi M; Amato MP; Trojano M; Neurol Neuroimmunol Neuroinflamm; 2022 Mar; 9(2):. PubMed ID: 35046084 [TBL] [Abstract][Full Text] [Related]
11. Analysis of Rituximab Use, Time Between Rituximab and SARS-CoV-2 Vaccination, and COVID-19 Hospitalization or Death in Patients With Multiple Sclerosis. Smith JB; Gonzales EG; Li BH; Langer-Gould A JAMA Netw Open; 2022 Dec; 5(12):e2248664. PubMed ID: 36576740 [TBL] [Abstract][Full Text] [Related]
12. Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis. Salter A; Fox RJ; Newsome SD; Halper J; Li DKB; Kanellis P; Costello K; Bebo B; Rammohan K; Cutter GR; Cross AH JAMA Neurol; 2021 Jun; 78(6):699-708. PubMed ID: 33739362 [TBL] [Abstract][Full Text] [Related]
13. COVID-19 in ocrelizumab-treated people with multiple sclerosis. Hughes R; Whitley L; Fitovski K; Schneble HM; Muros E; Sauter A; Craveiro L; Dillon P; Bonati U; Jessop N; Pedotti R; Koendgen H Mult Scler Relat Disord; 2021 Apr; 49():102725. PubMed ID: 33482590 [TBL] [Abstract][Full Text] [Related]
14. B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran. Safavi F; Nourbakhsh B; Azimi AR Mult Scler Relat Disord; 2020 Aug; 43():102195. PubMed ID: 32460086 [TBL] [Abstract][Full Text] [Related]
15. COVID-19 and disease-modifying therapies in patients with demyelinating diseases of the central nervous system: A systematic review. Sharifian-Dorche M; Sahraian MA; Fadda G; Osherov M; Sharifian-Dorche A; Karaminia M; Saveriano AW; La Piana R; Antel JP; Giacomini PS Mult Scler Relat Disord; 2021 May; 50():102800. PubMed ID: 33578206 [TBL] [Abstract][Full Text] [Related]
16. DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France. Sormani MP; Salvetti M; Labauge P; Schiavetti I; Zephir H; Carmisciano L; Bensa C; De Rossi N; Pelletier J; Cordioli C; Vukusic S; Moiola L; Kerschen P; Radaelli M; Théaudin M; Immovilli P; Casez O; Capobianco M; Ciron J; Trojano M; Stankoff B; Créange A; Tedeschi G; Clavelou P; Comi G; Thouvenot E; Battaglia MA; Moreau T; Patti F; De Sèze J; Louapre C; ; Ann Clin Transl Neurol; 2021 Aug; 8(8):1738-1744. PubMed ID: 34240579 [TBL] [Abstract][Full Text] [Related]
17. Humoral response to COVID-19 vaccination in MS patients on disease modifying therapy: Immune profiles and clinical outcomes. Holroyd KB; Healy BC; Conway S; Houtchens M; Bakshi R; Bhattacharyya S; Bose G; Galetta K; Kaplan T; Severson C; Singhal T; Stazzone L; Zurawski J; Polgar-Turcsanyi M; Saxena S; Paul A; Glanz BI; Weiner HL; Chitnis T Mult Scler Relat Disord; 2022 Nov; 67():104079. PubMed ID: 35952457 [TBL] [Abstract][Full Text] [Related]
18. Prevalence, severity, outcomes, and risk factors of COVID-19 in multiple sclerosis: An observational study in the Middle East. Alroughani R; Inshasi J; Al-Hashel J; Alkhaboury J; Alsalti A; Al Suwaidi R; Hassino LH; Farouk Ahmed S J Clin Neurosci; 2022 May; 99():311-316. PubMed ID: 35339046 [TBL] [Abstract][Full Text] [Related]